China clarifies standards for post-filed experimental data in Pfizer patent challenge
By MLex Staff ( July 8, 2026, 08:54 GMT | Insight) -- China's patent regulator has clarified the standards for evaluating post-filed experimental data in pharmaceutical patent challenges, citing a landmark Pfizer drug patent case to explain how such evidence should be assessed in invalidation proceedings.China's patent regulator has clarified the standards for evaluating post-filed experimental data in pharmaceutical patent challenges, citing a landmark Pfizer drug patent case to explain how such evidence should be assessed in invalidation proceedings. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.